Handelsavisen
prelaunch
Companies ›Healthcare ›INOD.NS
IN
INOD.NS — NSE (India) Biotechnology & Medical Research

Inod.Ns

$104,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,24 %
Op margin
17,2 %
ROE
20,7 %
Net margin
15,7 %
Debt / equity
0,19
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

INOD.NS operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Business. INOD.NS operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
20,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning INOD.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to INOD.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    INOD.NS operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    INOD.NS maintains a strong liquidity position with a current ratio of 5.31, indicating the company can cover its short-term liabilities more than five times over. However, the company's cash and equivalents of INR 2,478,440 are significantly lower than its long-term debt of INR 148,362,670, resulting in a net cash position that is negative after subtracting total debt. This suggests potential liquidity risk despite the high current ratio.

    The company's profitability is robust, with a return on equity of 20.72% and a return on assets of 16.63%, both exceeding the industry median for biotechnology and medical research firms. These metrics indicate efficient use of equity and assets to generate profit, aligning with the industry's preference for high ROIC and operating margins.

    INOD.NS's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This concentration increases exposure to market-specific risks, particularly in the healthcare diagnostics sector.

    The company's growth trajectory is positive, with a free cash flow of INR 160,017,870 and a capital expenditure of INR -8,621,000, suggesting reinvestment in operations and potential for future expansion. However, the absence of detailed revenue history limits the ability to assess long-term growth trends.

    Risk factors include medium liquidity risk due to the negative net cash position and the potential for dilution, although the risk is currently assessed as low. The company has not issued additional shares recently, and no dilution adjustments have been applied to the valuation metrics.

    Recent events include the publication of the latest financial statements, which show a net income of INR 162,674,250 and an operating income of INR 178,368,150. No significant regulatory or legal events have been disclosed in the available documents.

    Key takeaways
    • INOD.NS has a strong return on equity and assets, indicating efficient capital use.
    • The company's liquidity position is strong on paper but faces a negative net cash position after debt.
    • Revenue and operations are concentrated in a single segment, increasing market-specific risk.
    • Free cash flow is positive, supporting potential for reinvestment and growth.
    • Dilution risk is currently low, but the negative net cash position warrants monitoring.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $104,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $785.2M
    Net cashⓘ
    -$145.9M
    Current ratioⓘ
    5.3
    Debt / equityⓘ
    0.2
    ROAⓘ
    16.6%
    ROEⓘ
    20.7%
    Cash conversionⓘ
    9.0%
    CapEx / revenueⓘ
    -0.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries4
    EX21:3bc387f7d184EX21:3bc387f7d184Subsidiarie97%
    EX21:c5d8d649a514EX21:c5d8d649a514Subsidiarie97%
    EX21:ea2cc3a5150bEX21:ea2cc3a5150bSubsidiarie97%
    EX21:ee4e392fd5c3EX21:ee4e392fd5c3Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin17,2 %Above P75
    Net Margin15,7 %Above P75
    ROE20,7 %Above P75
    Capex / Rev-0,8 %Above P75
    D/E0,19Below median
    Cash Conv0,09Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 1 600 885 sh25 exercises5 insiders
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 134 059 @ $1,24exercise · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 65 941 @ $3,41exercise · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 94 059 @ $3,41exercise · 2026-06-15
    • MISHRA ASHOKEVP and COO · Stock Option (Right to Buy) → Common StockDisposed 26 666 @ $43,01exercise · 2026-06-02
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 105 586 @ $4,99exercise · 2026-05-29
    • Espineli Marissa BInterim CFO · Stock Option (Right to Buy) → Common StockDisposed 11 667 @ $3,41exercise · 2026-05-29
    • Espineli Marissa BInterim CFO · Stock Option (Right to Buy) → Common StockDisposed 8 000 @ $43,01exercise · 2026-05-29
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 38 056 @ $4,99exercise · 2026-05-22
    • FORLENZA LOUISE CDirector · Stock Option (Right to Buy) → Common StockDisposed 18 000 @ $1,24exercise · 2026-05-21
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $4,99exercise · 2026-05-21
    • FORLENZA LOUISE CDirector · Stock Option (Right to Buy) → Common StockDisposed 15 000 @ $1,24exercise · 2026-05-20
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $4,99exercise · 2026-05-20
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 2 800 @ $4,99exercise · 2026-05-19
    • FORLENZA LOUISE CDirector · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $1,24exercise · 2026-05-19
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $4,99exercise · 2026-05-18
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 100 000 @ $4,99exercise · 2026-05-15
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 76 991 @ $4,99exercise · 2026-05-14
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 34 967 @ $7,24exercise · 2026-05-13
    • Massey Stewart RDirector · Stock Option (Right to Buy) → Common StockDisposed 10 000 @ $7,24exercise · 2026-05-13
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 59 493 @ $4,99exercise · 2026-05-13
    • FORLENZA LOUISE CDirector · Stock Option (Right to Buy) → Common StockDisposed 10 000 @ $1,24exercise · 2026-05-12
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 26 666 @ $43,01exercise · 2026-05-12
    • ABUHOFF JACKDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 45 033 @ $7,24exercise · 2026-05-12
    • MISHRA ASHOKEVP and COO · Stock Option (Right to Buy) → Common StockDisposed 242 901 @ $4,99exercise · 2026-05-12
    • FORLENZA LOUISE CDirector · Stock Option (Right to Buy) → Common StockDisposed 20 000 @ $1,07exercise · 2026-05-12

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • INOD.NS Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,01 %$20M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$7M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$23M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$25M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$12M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$16M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$4M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$30M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$11M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$94M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$5M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$10M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$27M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$3M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$12M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$28M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$3M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 73 sellsnet -$158,3M9 insiders · last 365d
    • Chauhan JayantEVP and CFO · Common StockOther 8 889 · 2026-07-06
    • ABUHOFF JACKDirector, CEO · Common StockSold 16 869 @ $107,31$1,8M · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 19 103 @ $108,31$2,1M · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 54 411 @ $109,55$6,0M · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 41 593 @ $110,42$4,6M · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 42 870 @ $111,50$4,8M · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 23 592 @ $112,39$2,7M · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 1 562 @ $113,16$177K · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockOther 65 941 @ $3,41$225K · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockOther 134 059 @ $1,24$166K · 2026-06-16
    • ABUHOFF JACKDirector, CEO · Common StockSold 12 010 @ $103,49$1,2M · 2026-06-15
    • ABUHOFF JACKDirector, CEO · Common StockOther 94 059 @ $3,41$321K · 2026-06-15
    • ABUHOFF JACKDirector, CEO · Common StockSold 15 942 @ $104,64$1,7M · 2026-06-15
    • ABUHOFF JACKDirector, CEO · Common StockSold 25 653 @ $105,81$2,7M · 2026-06-15
    • ABUHOFF JACKDirector, CEO · Common StockSold 32 914 @ $106,52$3,5M · 2026-06-15
    • ABUHOFF JACKDirector, CEO · Common StockSold 6 240 @ $107,35$670K · 2026-06-15
    • ABUHOFF JACKDirector, CEO · Common StockSold 1 300 @ $108,50$141K · 2026-06-15
    • Callahan DonDirector · Common StockOther 1 481 · 2026-06-04
    • Clarke Richard DDirector · Common StockOther 1 481 · 2026-06-04
    • Massey Stewart RDirector · Common StockOther 1 481 · 2026-06-04
    • FORLENZA LOUISE CDirector · Common StockOther 1 481 · 2026-06-04
    • MISHRA ASHOKEVP and COO · Common StockSold 10 300 @ $113,75$1,2M · 2026-06-02
    • MISHRA ASHOKEVP and COO · Common StockOther 26 666 @ $43,01$1,1M · 2026-06-02
    • MISHRA ASHOKEVP and COO · Common StockSold 15 216 @ $114,67$1,7M · 2026-06-02
    • MISHRA ASHOKEVP and COO · Common StockSold 1 150 @ $115,37$133K · 2026-06-02

    Short positioning

    4.6Mshares short+28.0% vs prior
    4.25days to cover
    55.4%short of daily vol
    100fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    INOD.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    INODEX21:3bcEX21:c5dEX21:ea2EX21:ee4Biotechnology
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Return on assets (FY 2025-12-31): 19.1%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.57xDerived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 3.1%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 43.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 75.3%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 47.6%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 22.9%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 68.8%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 48.3%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 63.8%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 34.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 12.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 48.6%Derived (calculated)
    • Net margin (FY 2025-12-31): 12.8%Derived (calculated)
    • Gross margin (FY 2025-12-31): 39.5%Derived (calculated)
    • Return on equity (FY 2025-12-31): 30.0%Derived (calculated)
    • Current ratio (FY 2025-12-31): 2.68xDerived (calculated)
    • Shareholders' equity (annual): USD 107.14MSEC XBRL filing
    • Capex (annual): USD 11.1MSEC XBRL filing
    • Revenue (annual): USD 251.66MSEC XBRL filing
    • Operating cash flow (annual): USD 46.75MSEC XBRL filing
    • Cash & equivalents (annual): USD 82.23MSEC XBRL filing
    • Net income (annual): USD 32.18MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-06INSIDERChauhan Jayant transacted 8.9k sh — EVP and CFO
    2026-06-17FILINGFORM 8-K →
    2026-06-16 00:00 UTCINSIDER30 insider transactions — 2026-06 · net sell $34.5M 4 derivative
    2026-06-16INSIDERABUHOFF JACK sold 16.9k sh — Director, CEO ~$1.81M
    2026-06-16INSIDERABUHOFF JACK sold 19.1k sh — Director, CEO ~$2.07M
    2026-06-16INSIDERABUHOFF JACK sold 54.4k sh — Director, CEO ~$5.96M
    2026-06-16INSIDERABUHOFF JACK sold 41.6k sh — Director, CEO ~$4.59M
    2026-06-16INSIDERABUHOFF JACK sold 42.9k sh — Director, CEO ~$4.78M
    2026-06-16INSIDERABUHOFF JACK sold 23.6k sh — Director, CEO ~$2.65M
    2026-06-16INSIDERABUHOFF JACK sold 1.6k sh — Director, CEO ~$177k
    2026-06-16INSIDERABUHOFF JACK transacted 65.9k sh — Director, CEO ~$225k
    2026-06-16INSIDERABUHOFF JACK transacted 134.1k sh — Director, CEO ~$166k
    2026-06-16INSIDERABUHOFF JACK disposed of 65.9k sh Stock Option (Right to Buy) — Director, CEO
    2026-06-16INSIDERABUHOFF JACK disposed of 134.1k sh Stock Option (Right to Buy) — Director, CEO
    2026-06-15INSIDERABUHOFF JACK sold 12.0k sh — Director, CEO ~$1.24M
    2026-06-15INSIDERABUHOFF JACK transacted 94.1k sh — Director, CEO ~$321k
    2026-06-15INSIDERABUHOFF JACK sold 15.9k sh — Director, CEO ~$1.67M
    2026-06-15INSIDERABUHOFF JACK sold 25.7k sh — Director, CEO ~$2.71M
    2026-06-15INSIDERABUHOFF JACK sold 32.9k sh — Director, CEO ~$3.51M
    2026-06-15INSIDERABUHOFF JACK sold 6.2k sh — Director, CEO ~$670k
    2026-06-15INSIDERABUHOFF JACK sold 1.3k sh — Director, CEO ~$141k
    2026-06-15INSIDERABUHOFF JACK disposed of 94.1k sh Stock Option (Right to Buy) — Director, CEO
    2026-06-08FILINGFORM 8-K →
    2026-06-04INSIDERCallahan Don transacted 1.5k sh — Director
    2026-06-04INSIDERClarke Richard D transacted 1.5k sh — Director
    2026-06-04INSIDERMassey Stewart R transacted 1.5k sh — Director
    2026-06-04INSIDERFORLENZA LOUISE C transacted 1.5k sh — Director
    2026-06-02INSIDERMISHRA ASHOK sold 10.3k sh — EVP and COO ~$1.17M
    2026-06-02INSIDERMISHRA ASHOK transacted 26.7k sh — EVP and COO ~$1.15M
    2026-06-02INSIDERMISHRA ASHOK sold 15.2k sh — EVP and COO ~$1.74M
    2026-06-02INSIDERMISHRA ASHOK sold 1.1k sh — EVP and COO ~$133k
    2026-06-02INSIDERMISHRA ASHOK disposed of 26.7k sh Stock Option (Right to Buy) — EVP and COO
    2026-05-29 00:00 UTCINSIDER97 insider transactions — 2026-05 · net sell $114.3M 21 derivative
    2026-05-29INSIDEREspineli Marissa B disposed of 8.0k sh Stock Option (Right to Buy) — Interim CFO
    2026-05-29INSIDEREspineli Marissa B disposed of 11.7k sh Stock Option (Right to Buy) — Interim CFO
    2026-05-29INSIDERABUHOFF JACK disposed of 105.6k sh Stock Option (Right to Buy) — Director, CEO
    2026-05-22INSIDERABUHOFF JACK disposed of 38.1k sh Stock Option (Right to Buy) — Director, CEO
    2026-05-21INSIDERABUHOFF JACK disposed of 150.0k sh Stock Option (Right to Buy) — Director, CEO
    2026-05-21INSIDERFORLENZA LOUISE C disposed of 18.0k sh Stock Option (Right to Buy) — Director
    Showing the 40 most recent of 56 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage